NDC 50090-5508-01 - Lorazepam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-5508
- Requested NDC
- 50090-5508-01
- Package NDCs from labels
- 50090-5508-2, 50090-5508-0, 50090-5508-1, 50090-5508-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2026-01-24
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Lorazepam - A-S Medication Solutions | A-S Medication Solutions | 2026-01-24 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Related label |
|---|---|---|
| 50090-5508-0 | 2023-02-06 | Lorazepam Tablets, USP CIV Rx only |
| 50090-5508-1 | 2023-02-06 | Lorazepam Tablets, USP CIV Rx only |
| 50090-5508-2 | 2023-02-06 | Lorazepam Tablets, USP CIV Rx only |
| 50090-5508-0 | 2023-01-30 | Lorazepam Tablets, USP CIV Rx only |
| 50090-5508-1 | 2023-01-30 | Lorazepam Tablets, USP CIV Rx only |
| 50090-5508-2 | 2023-01-30 | Lorazepam Tablets, USP CIV Rx only |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-5508-0 | Lorazepam | 30 in 1 BOTTLE | TABLET | 30 | 9 | |
| 50090-5508-1 | Lorazepam | 100 in 1 BOTTLE | TABLET | 100 | 9 | |
| 50090-5508-2 | Lorazepam | 60 in 1 BOTTLE | TABLET | 60 | 9 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-5508 | LORAZEPAM TABLET [A-S MEDICATION SOLUTIONS] | 7 | Current NDC, Legacy NDC, 3 package rows | 20241115_8361519b-be1a-4542-a782-d7cdfa153e86.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-5508-0 | EA - Each | 50090-5508 | b2d8d933-6098-4d4f-8966-dc91477f2223 | 1 | 2024-12-10 |
| 50090-5508-1 | EA - Each | 50090-5508 | 7dbc1326-21c0-4da0-9db8-4829848c61c6 | 1 | 2024-12-10 |
| 50090-5508-2 | EA - Each | 50090-5508 | 3b7d0a63-e8bc-476b-8765-f77e8e269a98 | 1 | 2024-12-10 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 4a66b854-4dd6-3746-e054-00144ff8d46c | 2025-01-20 | Warnings, Adverse reactions | ANDA078203 197900 O26FZP769L |
| LORAZEPAM | LORAZEPAM | Advanced Rx of Tennessee, LLC | 2a57e549-390b-5482-e063-6394a90aeb3b | 2024-12-28 | Boxed warning, Warnings, Adverse reactions | 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 29f63525-2839-946c-e063-6294a90aebb1 | 2024-12-23 | Boxed warning, Warnings, Adverse reactions | 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | Fresenius Kabi USA, LLC | b2487467-a63f-48b5-b0de-3a6ce6672d50 | 2024-11-26 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 503834f9-fa2e-5e23-e054-00144ff88e88 | 2024-11-13 | Warnings, Adverse reactions | ANDA078203 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | A-S Medication Solutions | be85b116-9f09-403a-8e0d-e77e344d3a9a | 2024-11-13 | Boxed warning, Warnings, Adverse reactions | ANDA078203 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | Chartwell RX, LLC | 6b0619c5-b9e9-47e7-97b5-7e581e67cf5f | 2024-11-07 | Boxed warning, Warnings, Adverse reactions | 197901 197900 197902 O26FZP769L |
| Lorazepam | LORAZEPAM | Asclemed USA, Inc. | ebdf72f7-7462-4b83-81b4-c7988860c728 | 2024-11-05 | Boxed warning, Warnings, Adverse reactions | 197901 197900 197902 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals,Inc. | 8fa33078-c379-41f5-e053-2995a90acced | 2024-10-09 | Boxed warning, Warnings, Adverse reactions | 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 4a66b854-4dc1-3746-e054-00144ff8d46c | 2024-10-08 | Warnings, Adverse reactions | ANDA078203 197902 O26FZP769L |
| Lorazepam | LORAZEPAM | Bryant Ranch Prepack | 853c762d-0772-4f02-99ca-0bc2911f09f0 | 2024-08-26 | Boxed warning, Warnings, Adverse reactions | 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 4ab77192-8fe9-2965-e054-00144ff88e88 | 2024-07-19 | Warnings, Adverse reactions | ANDA078203 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals,Inc. | a4fe8df0-3ce8-b8b8-e053-2995a90a28f4 | 2024-07-17 | Boxed warning, Warnings, Adverse reactions | 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals, Inc. | 50379c41-2676-590c-e054-00144ff8d46c | 2024-07-08 | Warnings, Adverse reactions | ANDA078203 197901 O26FZP769L |
| Lorazepam | LORAZEPAM | Aphena Pharma Solutions - Tennessee, LLC | 1bcf608a-11c1-ec7d-e063-6394a90ab710 | 2024-06-26 | Boxed warning, Warnings, Adverse reactions | 197902 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals,Inc. | 8aace309-f3ef-6aef-e053-2995a90aa197 | 2024-06-19 | Boxed warning, Warnings, Adverse reactions | 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | NuCare Pharmaceuticals,Inc. | 933b5ef3-ec29-1a96-e053-2995a90a2d33 | 2024-06-19 | Boxed warning, Warnings, Adverse reactions | 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | Bryant Ranch Prepack | aac672f9-0ba7-4852-b8a7-caac9e4b1e77 | 2024-05-15 | Boxed warning, Warnings, Adverse reactions | ANDA078203 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | Proficient Rx LP | e9052b38-3c9f-4c84-9a0d-98bd99b9ddfd | 2024-05-01 | Boxed warning, Warnings, Adverse reactions | ANDA078203 197900 O26FZP769L |
| Lorazepam | LORAZEPAM | Aphena Pharma Solutions - Tennessee, LLC | e563594e-212c-4f31-92ea-294aeab45df3 | 2024-04-12 | Boxed warning, Warnings, Adverse reactions | ANDA078203 197900 O26FZP769L |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.